These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25982282)

  • 1. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
    Peyser ND; Freilino M; Wang L; Zeng Y; Li H; Johnson DE; Grandis JR
    Oncogene; 2016 Mar; 35(9):1163-9. PubMed ID: 25982282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
    Sen M; Kindsfather A; Danilova L; Zhang F; Colombo R; LaPorte MG; Kurland BF; Huryn DM; Wipf P; Herman JG
    Epigenetics; 2020; 15(6-7):604-617. PubMed ID: 31595832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
    Peyser ND; Du Y; Li H; Lui V; Xiao X; Chan TA; Grandis JR
    PLoS One; 2015; 10(8):e0135750. PubMed ID: 26267899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.
    Peyser ND; Pendleton K; Gooding WE; Lui VW; Johnson DE; Grandis JR
    PLoS One; 2016; 11(11):e0166185. PubMed ID: 27855189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
    Peyser ND; Wang L; Zeng Y; Acquafondata M; Freilino M; Li H; Sen M; Gooding WE; Satake M; Wang Z; Johnson DE; Grandis JR
    Cancer Prev Res (Phila); 2016 Aug; 9(8):657-63. PubMed ID: 27267892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
    Szaumkessel M; Wojciechowska S; Janiszewska J; Zemke N; Byzia E; Kiwerska K; Kostrzewska-Poczekaj M; Ustaszewski A; Jarmuz-Szymczak M; Grenman R; Wierzbicka M; Bartochowska A; Szyfter K; Giefing M
    Tumour Biol; 2017 Mar; 39(3):1010428317691427. PubMed ID: 28345455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
    Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
    Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the impact of STAT3 activation mediated by PTPRT promoter hypermethylation as biomarker of response to paclitaxel-plus-cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cirauqui BC; Peguera AB; Pi-Sunyer AQ; Ferrando-Díez A; Serrano JLR; Viñolas MD; García IT; García VQ; Oukadour IC; Valencia AG; Vergara PH; de Aguirre Egaña I; Herrero CQ; Carbonell OM; Paradís AL; Esteve A; Vila MM; Rosell R; Martínez-Cardús A; Mesía R
    Head Neck; 2025 Jan; 47(1):57-67. PubMed ID: 39072941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
    Lui VW; Peyser ND; Ng PK; Hritz J; Zeng Y; Lu Y; Li H; Wang L; Gilbert BR; General IJ; Bahar I; Ju Z; Wang Z; Pendleton KP; Xiao X; Du Y; Vries JK; Hammerman PS; Garraway LA; Mills GB; Johnson DE; Grandis JR
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1114-9. PubMed ID: 24395800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
    Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
    Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene promoter-associated CpG island hypermethylation in squamous cell carcinoma of the tongue.
    Bhat S; Kabekkodu SP; Jayaprakash C; Radhakrishnan R; Ray S; Satyamoorthy K
    Virchows Arch; 2017 Apr; 470(4):445-454. PubMed ID: 28255813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-κB and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma.
    Gaykalova DA; Manola JB; Ozawa H; Zizkova V; Morton K; Bishop JA; Sharma R; Zhang C; Michailidi C; Considine M; Tan M; Fertig EJ; Hennessey PT; Ahn J; Koch WM; Westra WH; Khan Z; Chung CH; Ochs MF; Califano JA
    Int J Cancer; 2015 Oct; 137(8):1879-89. PubMed ID: 25857630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
    Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
    PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
    Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
    Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors.
    Chen X; Liu L; Mims J; Punska EC; Williams KE; Zhao W; Arcaro KF; Tsang AW; Zhou X; Furdui CM
    Epigenetics; 2015; 10(6):545-61. PubMed ID: 25961636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma.
    Weiss D; Stockmann C; Schrödter K; Rudack C
    Cell Oncol (Dordr); 2013 Jun; 36(3):213-24. PubMed ID: 23529585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.
    Schmitt K; Molfenter B; Laureano NK; Tawk B; Bieg M; Hostench XP; Weichenhan D; Ullrich ND; Shang V; Richter D; Stögbauer F; Schroeder L; de Bem Prunes B; Visioli F; Rados PV; Jou A; Plath M; Federspil PA; Thierauf J; Döscher J; Weissinger SE; Hoffmann TK; Wagner S; Wittekindt C; Ishaque N; Eils R; Klussmann JP; Holzinger D; Plass C; Abdollahi A; Freier K; Weichert W; Zaoui K; Hess J
    Int J Cancer; 2019 Dec; 145(12):3299-3310. PubMed ID: 31135957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma.
    Steinmann K; Sandner A; Schagdarsurengin U; Dammann RH
    Oncol Rep; 2009 Dec; 22(6):1519-26. PubMed ID: 19885608
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
    Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.